Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 13, 2024

Total Value ($000): $197,873 (100.0% shares, 0.0% debt)

Holdings (5)

PHVS Pharvaris N.V. 57.3%

Value ($000) $113,290 Shares 4,038,842 Est. Cost $27.96 Unrealized -27.6%

KURA Kura Oncology, Inc. 13.4%

Value ($000) $26,602 Shares 1,849,947 Est. Cost $20.39 Unrealized -51.8%

— Kinnate Biopharma Inc. 11.6%

Value ($000) $22,922 Shares 9,671,643 Est. Cost $39.78 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 9.6%

Value ($000) $18,909 Shares 875,000 Est. Cost $22.62 Unrealized -32.1%

— Lyell Immunopharma, Inc. 8.2%

Value ($000) $16,151 Shares 8,325,000 Est. Cost $16.24 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	4,038,842	$113,290	57.3%	$27.96	-27.6%	COM	N69605108
KURA	Kura Oncology, Inc.	1,849,947	$26,602	13.4%	$20.39	-51.8%	COM	50127T109
—	Kinnate Biopharma Inc.	9,671,643	$22,922	11.6%	$39.78	—	COM	49705R105
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$18,909	9.6%	$22.62	-32.1%	COM	87164F105
—	Lyell Immunopharma, Inc.	8,325,000	$16,151	8.2%	$16.24	—	COM	55083R104